Bharat Biotech and GSK plc will significantly reduce the price of their malaria vaccine, Mosquirix, to under $5 per dose by 2028. This price cut, exceeding 50%, is part of their commitment to Gavi’s replenishment for 2026-2030. The companies attribute the reduction to manufacturing efficiencies, increased production, and minimal profit margins, aiming to enhance vaccine accessibility.
